| ||||
---|---|---|---|---|
Methods | Convenience sample: All patients with T2DM participating in an RCT (n = 89; 53 in the intervention arm, 36 in the control group) | Purposive sample: 30 patients with newly diagnosed T2DM participating in an RCT. Sampled to represent trial arm, recruitment site, and gender. | Purposive sample: 25 participants representing 4 groups depending on HbA1c control: ‘good’ (<7) or ‘poor’ (>9) (n = 13); or ‘improving’ or ‘deteriorating’ (n = 12) | Convenience sample: 40 patients with newly diagnosed T2DM. |
Sample | ||||
Diabetes duration at baseline (mean) | 6 years | 6 months | 6 years | 6 months |
Data collection | Cycles of semi-structured focus groups with all trial participants, pre- (n = 5) and post-intervention (n = 5). Group A at 6 and 12 months; Group B at 6 and 18 months; Group C at 12 months | Face to face interviews at 6 months (n = 30), and follow -up telephone interviews at 9 months (n = 29).( Trial paper [29] has 12mth data) | Semi structured face-to-face interviews at12 months (n = 25) ,and 24 months (n = 11).9 matched consultation sessions and telephone interviews at 36 months. | Semi structured face-to face interviews and fieldnotes at 0, 6, and 12 months (n = 40) and 48 months (n = 20). |
Analysis | Constant comparison. Source, method and theoretical triangulation. | Constant comparison. Thematic analysis. | Constant comparison. Thematic analysis. Construction of extended case reports over time. | Grounded theory [38, 39]; Thematic analysis [40, 45]; Longitudinal [11]; |
Setting | Primary and secondary care, England | Primary care, South West England | Primary care, deprived area in North West England. | Primary and secondary care, Scotland |
Trial design | 89 patients, randomised control wait list design Group A were randomly allocated to the treatment initially (n = 30), whilst the Group B acted as the short-term control group (n = 23) These two groups were then combined to form the short term trial group. | 593 patients randomly assigned in a 2:5:5 ratio. Control n = 99, Intensive Diet n = 249, Diet plus Activity n = 246 | 591 patients randomly allocated in a1:2 ratio. Control n = 197, Call-centre treatment support n = 394. | N/A. 40 patients with T2DM. Explorations of variance, location of care (12.5% primary care, 87.5% secondary care), diet, medication, class and gender. |
Group C received the intervention at the end of the trial period (n = 36). | Patients randomized to ‘usual care’ received standard advice about diet from trial dieticians at their baseline visit, and were seen by a doctor blinded to treatment at baseline, six and twelve months [28]. | Patients randomized to the ‘usual care’ group continued with conventional treatment based on local guidelines, which had been in place for over ten years, supported by a continuing education program among all primary care practices [34]. | ||
Intervention | 8 week educational programme including: physical activity, exercise, relaxation and health topics. | Intensive diet (ID) or intensive diet plus activity (IDPA) | Tele-care phone support, titrated to HbA1c, to improve blood glucose control | Not applicable |
Trial results | At 6 months, intervention associated with benefits in HbA1c levels (−0.1%), illness attitudes, and perceived treatment effectiveness, compared to controls. At 12 months, only illness attitudes and self-monitoring showed benefit [27]. | At 6 and 12 months, glycaemic control had improved in the diet (−0.28%) and diet/activity groups (−0.33%), but worsened in the control group [29] | At 12 months, compared with the control group, HbA1c improved by 0.31% in the intervention group, and the improvement was significantly greater for those with a baseline HbA1c > 7% [30]. | Not applicable |
At 12 months, the control group saw an improvement in their understanding, expectation of disease continuation, and concern of their illness; while the intervention groups increased their understanding, became less concerned, felt more in control of their illness, were more satisfied with their diabetes treatment, and had higher self-reported health scores [30]. | At 12 months, the intervention group continued to report high levels of satisfaction with their treatment [34] | |||
At 36 months, there was a statistically significant reduction of HbA1c by 0.24% attributable to the intervention [36]. |